A third dose of an mRNA COVID-19 vaccine can be beneficial in individuals undergoing treatment for MS who had weak immune responses to previous doses, indicate new data published in JAMA Neurology. Researchers gave a third dose of mRNA COVID-19 vaccine to 130 patients receiving immunotherapy for MS who had low levels of SARS-CoV-2 spike antibodies despite two previous vaccine doses. After the third dose, 27 participants had SARS-CoV-2 spike antibody levels that indicated protective humoral immunity.
References
Original article
König, M. et al. Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2021.5109 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lemprière, S. Third COVID-19 jab benefits people with MS. Nat Rev Neurol 18, 127 (2022). https://doi.org/10.1038/s41582-022-00625-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00625-w
